Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

IPSS-m outperforms IPSS-R in younger adults with Myelodysplastic Syndromes: A retrospective age-stratified analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJin-Jun YangYZYa ZhangYWYu Wu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows IPSS-M offers better risk stratification, improving survival predictions in younger adults with MDS.

Key Points

  • This study aims to determine the prognostic accuracy of IPSS-M compared to IPSS-R in younger adults with Myelodysplastic Syndromes (MDS).
  • Retrospective analysis of 202 MDS patients from West China Hospital (2015-2022)
  • Patients divided by age: <50 years (53) and ≥50 years (149)
  • Data collected included clinical, laboratory, cytogenetic, and next-generation sequencing
  • Kaplan–Meier analysis to estimate overall survival and log-rank test for comparisons
  • Older patients had more comorbidities, while younger patients were more likely to receive stem cell transplantation
  • Significantly fewer mutations in age-associated genes (DNMT3A, ASXL1, TET2) in younger patients
  • Median overall survival was longer in younger patients (17.2 months) compared to older patients (13.6 months)
  • IPSS-M distinguished survival risk in younger cohorts, while IPSS-R did not

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6achttps://doi.org/10.1182/blood-2025-7391
View Full Paper
Ask AI
Bookmark
Share